| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |



From the Department of Endocrinology and Metabolic
Diseases,*
and the Department of Immunohaematology and the
Bloodbank,
Leiden University Medical Center,
Leiden; and the Nederlandse Organisatie voor Toegepast
Natuurwetenschappelijk Onderzock-Preventie en Gezonheid Gaubius
Laboratory,
Leiden, The Netherlands
Interactions between specific cell-surface molecules,
which include the urokinase receptor (uPAR) and integrins, are
crucial to processes of tumor invasion and metastasis. Here we
demonstrate that uPAR and ß1-integrins may cluster at distinct sites
at the cell surface of metastatic MDA-MB-231 breast cancer cells and
form functional complexes. Attachment assays performed in the presence
of a synthetic peptide (p25), which interferes with the
formation of uPAR-integrin complexes, reveal that uPAR is able
to regulate the adhesive function of integrins in breast cancer cells.
On dissociation of the uPAR-integrin complexes by p25, tumor
cell attachment to the extracellular matrix was either decreased
(vitronectin) or increased (fibronectin). Moreover, the tumor
cells display remarkable morphological changes when cultured on
fibronectin in the continuous presence of p25, leading to
increased cell spreading and attachment. In marked contrast to control
conditions, increased cellular adhesion to fibronectin after
p25 treatment was entirely ß1-integrin-mediated. The role of
uPAR-integrin complexes in tumor progression was studied in an
in vivo bone xenograft model. Stably transfected
MDA-MB-231 cells that overexpress p25 showed a significant reduction in
tumor progression in bone (P
0.0001
versus mock-control). In line with these
observations, continuous administration of p25 (25
µg/mouse/day, osmotic minipumps) for 28 days resulted in
significantly reduced tumor progression of MDA-MB-231 cells in bone
(P
0.005) when compared to scrambled control
peptide. In conclusion, our data demonstrate that uPAR can act
as an adhesion receptor in breast cancer and is capable of regulating
integrin function. Our findings strongly suggest that adhesive and
proteolytic events are tightly associated in metastatic breast cancer
cells and that functional integrin-uPAR complexes are involved in tumor
progression in vivo.
This article has been cited by other articles:
![]() |
J.-W. Liu, P. Sun, Q. Yan, A. S. Paller, P. Gerami, N. Ho, N. Vashi, I. C. Le Poole, and X.-q. Wang De-N-acetyl GM3 Promotes Melanoma Cell Migration and Invasion through Urokinase Plasminogen Activator Receptor Signaling-Dependent MMP-2 Activation Cancer Res., November 15, 2009; 69(22): 8662 - 8669. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jo, S. Takimoto, V. Montel, and S. L. Gonias The Urokinase Receptor Promotes Cancer Metastasis Independently of Urokinase-Type Plasminogen Activator in Mice Am. J. Pathol., July 1, 2009; 175(1): 190 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Young, D. K. Pearl, and J. R. Van Brocklyn Sphingosine-1-Phosphate Regulates Glioblastoma Cell Invasiveness through the Urokinase Plasminogen Activator System and CCN1/Cyr61 Mol. Cancer Res., January 1, 2009; 7(1): 23 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Monaghan-Benson, C. C. Mastick, and P. J. McKeown-Longo A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR J. Cell Sci., November 15, 2008; 121(22): 3693 - 3703. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Mazar Urokinase Plasminogen Activator Receptor Choreographs Multiple Ligand Interactions: Implications for Tumor Progression and Therapy Clin. Cancer Res., September 15, 2008; 14(18): 5649 - 5655. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Monaghan-Benson and P. J. McKeown-Longo Urokinase-type Plasminogen Activator Receptor Regulates a Novel Pathway of Fibronectin Matrix Assembly Requiring Src-dependent Transactivation of Epidermal Growth Factor Receptor J. Biol. Chem., April 7, 2006; 281(14): 9450 - 9459. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Kwak, S. Mitra, K. Bdeir, D. Strassheim, J. S. Park, J. Y. Kim, S. Idell, D. Cines, and E. Abraham The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins J. Leukoc. Biol., October 1, 2005; 78(4): 937 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. van der Pluijm, I. Que, B. Sijmons, J. T. Buijs, C. W.G.M. Lowik, A. Wetterwald, G. N. Thalmann, S. E. Papapoulos, and M. G. Cecchini Interference with the Microenvironmental Support Impairs the De novo Formation of Bone Metastases In vivo Cancer Res., September 1, 2005; 65(17): 7682 - 7690. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wei, R.-P. Czekay, L. Robillard, M. C. Kugler, F. Zhang, K. K. Kim, J.-p. Xiong, M. J. Humphries, and H. A. Chapman Regulation of {alpha}5{beta}1 integrin conformation and function by urokinase receptor binding J. Cell Biol., January 31, 2005; 168(3): 501 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mayasundari, N. A. Whittemore, E. H. Serpersu, and C. B. Peterson The Solution Structure of the N-terminal Domain of Human Vitronectin: PROXIMAL SITES THAT REGULATE FIBRINOLYSIS AND CELL MIGRATION J. Biol. Chem., July 9, 2004; 279(28): 29359 - 29366. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Monaghan, V. Gueorguiev, C. Wilkins-Port, and P. J. McKeown-Longo The Receptor for Urokinase-type Plasminogen Activator Regulates Fibronectin Matrix Assembly in Human Skin Fibroblasts J. Biol. Chem., January 9, 2004; 279(2): 1400 - 1407. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kawasaki, T. Maeda, K. Hanasawa, I. Ohkubo, and T. Tani Effect of His-Gly-Lys Motif Derived from Domain 5 of High Molecular Weight Kininogen on Suppression of Cancer Metastasis Both in Vitro and in Vivo J. Biol. Chem., December 5, 2003; 278(49): 49301 - 49307. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Montuori, M. V. Carriero, S. Salzano, G. Rossi, and P. Ragno The Cleavage of the Urokinase Receptor Regulates Its Multiple Functions J. Biol. Chem., November 27, 2002; 277(49): 46932 - 46939. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Leksa, S. Godar, M. Cebecauer, I. Hilgert, J. Breuss, U. H. Weidle, V. Horejsi, B. R. Binder, and H. Stockinger The N Terminus of Mannose 6-Phosphate/Insulin-like Growth Factor 2 Receptor in Regulation of Fibrinolysis and Cell Migration J. Biol. Chem., October 18, 2002; 277(43): 40575 - 40582. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. H. de Groot, H. J. Broxterman, H. P. H. M. Adams, A. van Vliet, G. I. Tesser, Y. W. Elderkamp, A. J. Schraa, R. Jan Kok, G. Molema, H. M. Pinedo, et al. Design, Synthesis, and Biological Evaluation of a Dual Tumor-specific Motive Containing Integrin-targeted Plasmin-cleavable Doxorubicin Prodrug Mol. Cancer Ther., September 1, 2002; 1(11): 901 - 911. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Rabbani and J. Gladu Urokinase Receptor Antibody Can Reduce Tumor Volume and Detect the Presence of Occult Tumor Metastases in Vivo Cancer Res., April 1, 2002; 62(8): 2390 - 2397. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |